Natalie Percival1, Angela George2, Jennifer Gyertson3, Monica Hamill3, Andreia Fernandes4, Emily Davies4, Nazneen Rahman5, Susana Banerjee6. 1. Advanced Nurse Practitioner, Gynaecology Unit, The Royal Marsden NHS Foundation Trust. 2. Consultant Oncogenetics, Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Division of Genetics and Epidemiology, The Institute of Cancer Research, London. 3. Research Nurse, Gynaecology Unit, The Royal Marsden NHS Foundation Trust. 4. Clinical Nurse Specialist, Gynaecology Unit, The Royal Marsden NHS Foundation Trust. 5. Professor of Genetics, The Royal Marsden NHS Foundation Trust and Division of Genetics and Epidemiology, The Institute of Cancer Research, London. 6. Consultant Medical Oncologist, Gynaecology Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London.
Abstract
PURPOSE: The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, such as the mainstreaming oncogenetic pathway, involving oncology health professionals are being used. The authors report on the establishment of the extended role of the clinical nurse specialist in consenting women for BRCA testing in routine gynaecology-oncology clinics using the mainstreaming model. METHODS: Nurses undertook generic consent training and specific counselling training for BRCA testing in the form of a series of online videos, written materials and checklists before obtaining approval to consent patients for germline BRCA1 and BRCA2 mutations. RESULTS: Between July 2013 and December 2015, 108 women with ovarian cancer were counselled and consented by nurses in the medical oncology clinics at a single centre (The Royal Marsden, UK). This represented 36% of all ovarian cancer patients offered BRCA testing in the oncology clinics at the centre. Feedback from patients and nurses was encouraging with no significant issues raised in the counselling and consenting process. CONCLUSION: The mainstreaming model allows for greater access to BRCA testing for ovarian cancer patients, many of whom may benefit from personalised therapy (PARP inhibitors). This is the first report of oncology nurses in the BRCA testing pathway. Specialist oncology nurses trained in BRCA testing have an important role within a multidisciplinary team counselling and consenting patients to undergo BRCA testing.
PURPOSE: The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, such as the mainstreaming oncogenetic pathway, involving oncology health professionals are being used. The authors report on the establishment of the extended role of the clinical nurse specialist in consenting women for BRCA testing in routine gynaecology-oncology clinics using the mainstreaming model. METHODS: Nurses undertook generic consent training and specific counselling training for BRCA testing in the form of a series of online videos, written materials and checklists before obtaining approval to consent patients for germline BRCA1 and BRCA2 mutations. RESULTS: Between July 2013 and December 2015, 108 women with ovarian cancer were counselled and consented by nurses in the medical oncology clinics at a single centre (The Royal Marsden, UK). This represented 36% of all ovarian cancerpatients offered BRCA testing in the oncology clinics at the centre. Feedback from patients and nurses was encouraging with no significant issues raised in the counselling and consenting process. CONCLUSION: The mainstreaming model allows for greater access to BRCA testing for ovarian cancerpatients, many of whom may benefit from personalised therapy (PARP inhibitors). This is the first report of oncology nurses in the BRCA testing pathway. Specialist oncology nurses trained in BRCA testing have an important role within a multidisciplinary team counselling and consenting patients to undergo BRCA testing.
Entities:
Keywords:
BRCA; Clinical nurse specialist; Family history; Genetic testing; Ovarian cancer
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis Journal: Lancet Oncol Date: 2014-05-31 Impact factor: 41.316
Authors: Evan J Walker; Julia Carnevale; Christina Pedley; Amie Blanco; Salina Chan; Eric A Collisson; Margaret A Tempero; Andrew H Ko Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Terri Patricia McVeigh; Karl J Sweeney; Donal J Brennan; Una M McVeigh; Simon Ward; Ann Strydom; Sheila Seal; Katherine Astbury; Paul Donnellan; Joanne Higgins; Maccon Keane; Michael J Kerin; Carmel Malone; Pauline McGough; Ray McLaughlin; Michael O'Leary; Margaret Rushe; Michael Kevin Barry; Geraldine MacGregor; Michael Sugrue; Ala Yousif; Dhafir Al-Azawi; Eileen Berkeley; Terence J Boyle; Elizabeth M Connolly; Carmel Nolan; Elaine Richardson; Claire Giffney; Samantha B Doyle; Sheila Broderick; William Boyd; Ruaidhri McVey; Thomas Walsh; Michael Farrell; David J Gallagher; Nazneen Rahman; Angela J George Journal: Fam Cancer Date: 2022-08-27 Impact factor: 2.446
Authors: Koji Shindo; Jun Yu; Masaya Suenaga; Shahriar Fesharakizadeh; Christy Cho; Anne Macgregor-Das; Abdulrehman Siddiqui; P Dane Witmer; Koji Tamura; Tae Jun Song; Jose Alejandro Navarro Almario; Aaron Brant; Michael Borges; Madeline Ford; Thomas Barkley; Jin He; Matthew J Weiss; Christopher L Wolfgang; Nicholas J Roberts; Ralph H Hruban; Alison P Klein; Michael Goggins Journal: J Clin Oncol Date: 2017-08-02 Impact factor: 44.544
Authors: Maria I Carlo; Veda N Giri; Channing J Paller; Wassim Abida; Joshi J Alumkal; Tomasz M Beer; Himisha Beltran; Daniel J George; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Charles J Ryan; Edward M Schaeffer; Walter M Stadler; Mary-Ellen Taplin; Noah D Kauff; Jacob Vinson; Emmanuel S Antonarakis; Heather H Cheng Journal: JCO Precis Oncol Date: 2018-08-16
Authors: Jong Y Park; Cecile A Lengacher; Richard R Reich; Carissa B Alinat; Sophia Ramesar; Alice Le; Carly L Paterson; Michelle L Pleasant; Hyun Y Park; John Kiluk; Hyo Han; Roohi Ismail-Khan; Kevin E Kip Journal: Transl Behav Med Date: 2019-07-16 Impact factor: 3.626